Allogene Therapeutics ALLO Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's preferred stock, par or stated value per share?
- Allogene Therapeutics (ALLO) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Allogene Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Allogene Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Allogene Therapeutics's preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Allogene Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.